<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.116361</article-id><article-id pub-id-type="publisher-id">ACM-42928</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210600000_98655639.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  IgD型浆母细胞骨髓瘤一例报告并文献复习
  IgD Plasmablastic Plasma Cell Myeloma: A Case Report and Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>晶晶</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>聂</surname><given-names>淑敏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>俊霞</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>田兰</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>静静</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>献启</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院神经内科，山东 青岛</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属医院血液科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>01</day><month>06</month><year>2021</year></pub-date><volume>11</volume><issue>06</issue><fpage>2514</fpage><lpage>2520</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨浆母细胞骨髓瘤患者的临床特征、诊治和预后。方法：报道1例IgD型浆母细胞骨髓瘤患者的诊疗，结合文献复习，探讨该疾病的发病机制、诊断、治疗与预后特征。结果：患者，男，53岁，确诊为IgD型浆母细胞骨髓瘤。给予包含硼替佐米在内的多个疗程的化疗后，疾病仍然进展。患者因肿瘤累及椎管行肿瘤切除术，腰椎肿物病理示浆细胞骨髓瘤(浆母细胞型)，术后3个月内死亡，总生存期：18个月。结论：IgD型和浆母细胞骨髓瘤均较罕见，二者存活时间短，预后差。浆母细胞骨髓瘤病因尚不清楚，临床表现无特异性，确诊主要依靠病理及免疫组织化学检查，目前尚无标准的治疗方案，多用类似于多发性骨髓瘤治疗的方案，包括新药在内的高强度化疗以及自体造血干细胞移植可能疗效更好。
   Objective: To investigate the clinical features, diagnosis, therapy and prognosis of IgD plasmablastic plasma cell myeloma. Methods: The diagnosis and therapy of a patient with IgD plasmablastic plasma cell myeloma were reported, and the pathogenesis, diagnosis, therapy and prognosis of the disease were discussed in combination with literature review. Results: The patient, a 53-year-old man, was diagnosed with IgD plasmablastic plasma cell myeloma. Progressive disease remains after multiple courses of chemotherapy including bortezomib. The patient underwent tumor resection due to tumor involving the spinal canal, pathology of the lumbar mass showed plasmablastic plasma cell myeloma, and the patient died within 3 months after surgery, with an overall survival of 18 months. Conclusion: IgD and plasmablastic plasma cell myelomas were extremely rare. These patients usually had a poor prognosis. Its pathogenesis remained to be unclear. With non-specific clinical manifestations, the diagnosis was mainly confirmed by histopathological and immunohistochemical staining method. Without standard treatment, these patients were treated with chemotherapy regimens, including new drugs, high-intensity chemotherapy and autologous hematopoietic stem cells.
 
</p></abstract><kwd-group><kwd>浆母细胞，多发性骨髓瘤，IgD，治疗，预后, Plasmablastic</kwd><kwd> Multiple Myeloma</kwd><kwd> IgD</kwd><kwd> Treatment</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨浆母细胞骨髓瘤患者的临床特征、诊治和预后。方法：报道1例IgD型浆母细胞骨髓瘤患者的诊疗，结合文献复习，探讨该疾病的发病机制、诊断、治疗与预后特征。结果：患者，男，53岁，确诊为IgD型浆母细胞骨髓瘤。给予包含硼替佐米在内的多个疗程的化疗后，疾病仍然进展。患者因肿瘤累及椎管行肿瘤切除术，腰椎肿物病理示浆细胞骨髓瘤(浆母细胞型)，术后3个月内死亡，总生存期：18个月。结论：IgD型和浆母细胞骨髓瘤均较罕见，二者存活时间短，预后差。浆母细胞骨髓瘤病因尚不清楚，临床表现无特异性，确诊主要依靠病理及免疫组织化学检查，目前尚无标准的治疗方案，多用类似于多发性骨髓瘤治疗的方案，包括新药在内的高强度化疗以及自体造血干细胞移植可能疗效更好。</p></sec><sec id="s2"><title>关键词</title><p>浆母细胞，多发性骨髓瘤，IgD，治疗，预后</p></sec><sec id="s3"><title>IgD Plasmablastic Plasma Cell Myeloma: A Case Report and Literature Review</title><p>Jingjing Xiao<sup>1</sup>, Shumin Nie<sup>2</sup>, Junxia Huang<sup>3</sup>, Tianlan Li<sup>3</sup>, Jingjing Zhou<sup>3</sup>, Xianqi Feng<sup>3*</sup></p><p><sup>1</sup>Department of Medicine, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><sup>3</sup>Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/3-1572229x4_hanspub.png" /></p><p>Received: May 1<sup>st</sup>, 2021; accepted: May 13<sup>th</sup>, 2021; published: Jun. 7<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-1572229x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the clinical features, diagnosis, therapy and prognosis of IgD plasmablastic plasma cell myeloma. Methods: The diagnosis and therapy of a patient with IgD plasmablastic plasma cell myeloma were reported, and the pathogenesis, diagnosis, therapy and prognosis of the disease were discussed in combination with literature review. Results: The patient, a 53-year-old man, was diagnosed with IgD plasmablastic plasma cell myeloma. Progressive disease remains after multiple courses of chemotherapy including bortezomib. The patient underwent tumor resection due to tumor involving the spinal canal, pathology of the lumbar mass showed plasmablastic plasma cell myeloma, and the patient died within 3 months after surgery, with an overall survival of 18 months. Conclusion: IgD and plasmablastic plasma cell myelomas were extremely rare. These patients usually had a poor prognosis. Its pathogenesis remained to be unclear. With non-specific clinical manifestations, the diagnosis was mainly confirmed by histopathological and immunohistochemical staining method. Without standard treatment, these patients were treated with chemotherapy regimens, including new drugs, high-intensity chemotherapy and autologous hematopoietic stem cells.</p><p>Keywords:Plasmablastic, Multiple Myeloma, IgD, Treatment, Prognosis</p><disp-formula id="hanspub.42928-formula18"><graphic xlink:href="//html.hanspub.org/file/3-1572229x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1572229x8_hanspub.png" /> <img src="//html.hanspub.org/file/3-1572229x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>多发性骨髓瘤(multiple myeloma, MM)是骨髓浆细胞恶性增殖性疾病，可破坏骨骼和肾脏及机体的造血功能。MM发病率居血液肿瘤第2位，最常见于65~74岁的人群 [<xref ref-type="bibr" rid="hanspub.42928-ref1">1</xref>]。MM主要是由分化良好的肿瘤浆细胞组成，在形态上与正常浆细胞及效应浆细胞相似；也有一些罕见的MM细胞形态，如多叶细胞、多形细胞、浆母细胞、印戒细胞、小细胞、组织细胞样细胞、透明细胞和梭形细胞 [<xref ref-type="bibr" rid="hanspub.42928-ref2">2</xref>]。其中，浆母细胞骨髓瘤(plasmablastic plasma cell myeloma, PPCM)是一种非常罕见的多发性骨髓瘤的形态学亚型，据报道预后相对较差 [<xref ref-type="bibr" rid="hanspub.42928-ref3">3</xref>]；IgD型多发性骨髓瘤是一种少见的骨髓瘤类型。目前IgD型浆母细胞骨髓瘤鲜有报道。PPCM与其他侵袭性肿瘤，如浆母细胞淋巴瘤、间变性浆细胞骨髓瘤等不易区分，误诊可能导致不恰当的治疗。随着蛋白酶体抑制剂及免疫调节剂的出现，新药明显改善了骨髓瘤患者疗效和预后，但目前国际上MM预后分层系统仍不能满足临床上对于浆母细胞型、IgD型、间变型等罕见骨髓瘤的临床需要。为了加深对PPCM的认识，我们在病例分析的基础上对PPCM的临床表现、鉴别诊断、实验室检查、组织病理学特征、治疗以及预后方面复习了相关文献。</p></sec><sec id="s6"><title>2. 病例资料</title><p>患者男，53岁，汉族，因“胸背疼痛3天”于2017.9.22首次就诊于青岛大学附属医院血液科。患者3天前出现胸背疼痛，活动时加重，于当地医院行胸部CT示胸椎诸椎体、胸骨及双侧肋骨骨质破坏，考虑骨髓瘤可能性大。既往20年前行阑尾切除术。入院查体：左侧肋骨、胸骨及胸椎多处压痛阳性。实验室检查：血红蛋白104.00 g/L。肝、肾功能未见明显异常，M蛋白未见。血沉79.1 mm/h↑，血钙2.31 mmol/L，β2微球蛋白1.96 mg/L；血免疫球蛋白IgA &lt; 0.26 g/L↓，IgM &lt; 0.17 g/L↓，IgE &lt; 17.70 IU/ml，IgG 3.64 g/L↓，轻链：κ轻链0.71 g/L↓，λ轻链4.26 g/L↑，κ/λ：0.17↓。免疫固定电泳–血Ig(G、A、M)：在β-γ区可见两条单克隆轻链λ成分；免疫固定电泳(尿)：在β区可见一条单克隆轻链λ成分。骨髓形态学：浆细胞占1%。免疫分型：骨髓中检出0.4%的异常浆细胞，表达CD38、CD138，Lambda单克隆表达。骨髓活检：浆细胞肿瘤伴骨髓纤维化。骨髓增生极度活跃(&gt;90%)，异型细胞增生为主。免疫组化：CD38 (+)、CD138 (+)、MUM1 (+)，Lambda+，Kappa−，CD56−、CD20−、CD3−、CD34−、MPO−。FISH：TP53、CKS1B、CDKN2C、RB-1基因未见异常，IgH基因重排阴性。染色体为正常核型。影像学：胸椎、胸骨及双侧肋骨骨质破坏。结合患者症状、体征、实验室检查及骨髓相关检查，初步诊断：多发性骨髓瘤(λ轻链型，DS分期I期A，ISS分期I期，R-ISS分期I期)、多发骨质破坏、轻度贫血、骨髓纤维化。</p><p>患者接受4个疗程PAD方案(硼替佐米、表柔比星、地塞米松)，2018.2.6复查，形态学未见骨髓瘤细胞。免疫分型：检出0.5%的异常浆细胞群，主要表达CD38、CD138，Lambda单克隆表达。骨髓活检：粒红巨三系细胞少见伴异型细胞增生。染色体为正常核型。24 h尿λ轻链排泄量：1272.00 mg/24小时。血清免疫固定电泳：在β-γ区可见两条单克隆轻链λ成分。尿免疫固定电泳：在β区可见一条单克隆轻链λ成分；影像学较前无明显变化。评估：SD；患者继续接受2个疗程VTD (硼替佐米、沙利度胺、地塞米松)、3个疗程VRD方案(硼替佐米、来那度胺、地塞米松)；2018.7.30复查，骨髓形态：全片分类不明细胞占32%，其细胞胞体大，形状不规则，核大，略偏位，类圆形，双核及扭曲折叠均可见，形似骨髓瘤细胞。免疫分型：CD45阴性区域见1.3%的浆细胞，主要表达CD38，CD138，Lambda轻链单克隆阳性。另见3.3%的异常浆细胞群，主要表达CD45str、CD38、CD138、CD56、CD33，Lambda轻链单克隆阳性。骨髓活检：少部分区域增生极度活跃，异常细胞增生，考虑为异常浆细胞。染色体为正常核型。FISH未见异常。血清游离轻链：κ轻链6.4 mg/L，λ轻链216 mg/L，κ/λ：0.029↓。免疫固定电泳(血、尿)：在γ区可见一条单克隆轻链λ成分。影像学：MRI示胸椎、附件及肋骨、腰椎多发异常信号，符合多发性骨髓瘤；CT示双侧肋骨、胸椎、腰椎及骨盆弥漫性斑片状溶骨性骨质破坏，边缘略示硬化。评估：PD。此后患者接受2个疗程VRD方案后出院，自行延长化疗间隔3个月。</p><p>患者于2018.12.12出现腰背部剧烈疼痛，再次入院。复查影像学CT：颅骨、胸骨、腰椎、胸椎、骨盆骨质破坏，较前增多。MR：胸椎、腰椎、附件及肋骨多发异常信号，符合多发性骨髓瘤表现；T4、8、9椎体略变扁，考虑压缩性骨折。骨髓涂片未见骨髓瘤细胞。免疫分型：0.8%骨髓瘤细胞，表达CD38，CD138部分表达。24h尿λ轻链排泄量：1236.60 mg/24小时。血清免疫固定电泳Ig (G、A、M、D)：在γ区可见一条单克隆IgDλ成分。尿免疫固定电泳IG (G、A、M、D)：在λ区可见一条单克隆轻链λ成分。此时患者更新诊断为多发性骨髓瘤(IgD-λ轻链型)、多发骨质破坏、腰椎压缩性骨折。行硼替佐米 + VAD方案(长春地辛、表柔比星、地塞米松)；11天后，患者出现双下肢无力，大小便失禁。复查MRI：T12-L1水平椎管内异常信号影并椎管狭窄，考虑肿瘤累及可能性，多发性骨髓瘤髓外浸润？截瘫、脊髓损伤。</p><p>图1. 肿瘤组织病理学特征：肿瘤细胞染色质疏松，核仁明显，呈圆形、椭圆形核或者不规则形；胞质较少，核质比较高。HE染色，&#215;400</p><p>图2. 肿瘤免疫组织化学染色。(A) 骨髓瘤细胞膜广泛表达CD38，&#215;400；(B) 骨髓瘤细胞膜广泛表达CD138，&#215;400</p><p>给予患者肿瘤切除术及化疗，肿瘤组织病理学：浆细胞骨髓瘤(浆母细胞型) (见图1)；免疫组化(见图2)：CD38 (部分+)，CD138 (+)，Kappa少数(+)，Lambda (+)，CD20 (−)，CD3 (−)，CD79a (−)，MPO部分(+)，MUM1部分(+)，Ki-67 (+)约80%；EBER (原位杂交) (−)。患者于2019年1月30日接受高三尖杉酯碱 + 依托泊苷 + 地塞米松方案化疗，化疗期间出现严重感染，败血症。患者及家属放弃治疗，于2019.3.17死亡，总生存期：18个月。</p></sec><sec id="s7"><title>3. 讨论及文献复习</title><p>本例患者以骨痛、骨质破坏起病，免疫固定电泳提示λ轻链型，DS分期为I期A，ISS及R-ISS分期均为I期，无高危遗传学异常，传统风险分层及mSMART危险分层均为低危，更换多种治疗方案，疗效仍然较差；疾病进展后经外单位IgD型免疫固定电泳检测，在γ区可见一条单克隆IgDλ成分，最终明确诊断为MM (IgD-λ型)。因此临床上当怀疑骨髓瘤诊断并且在血清或尿液中未检测到或仅检测到单克隆轻链时，有必要筛查患者是否存在IgD或IgE单克隆蛋白 [<xref ref-type="bibr" rid="hanspub.42928-ref4">4</xref>]。本病例患者，在初诊时拒绝外送标本进一步检测D/E免疫固定电泳检测，故本患者最初诊断为MM (λ轻链型，DS分期I期A，ISS分期I期，R-ISS分期I期)、多发骨质破坏、轻度贫血、骨髓纤维化。</p><p>IgD型MM是一种较少见的骨髓瘤类型，国外报道占2%左右，国内报道IgD型占2.0%~8.9% [<xref ref-type="bibr" rid="hanspub.42928-ref5">5</xref>]。IgD型MM发病率低，以λ轻链型为主，贫血、肾损害、高钙血症、LDH升高及髓外浸润等临床表现更突出，多伴随t (11; 14) [<xref ref-type="bibr" rid="hanspub.42928-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.42928-ref7">7</xref>]。目前的骨髓瘤临床分期系统对预测MM患者的预后非常重要，但这些分期系统不包括IgD骨髓瘤 [<xref ref-type="bibr" rid="hanspub.42928-ref8">8</xref>]。对罕见MM亚型中已知的预后因素进行验证是指导临床治疗的必要条件 [<xref ref-type="bibr" rid="hanspub.42928-ref9">9</xref>]。2000年后MM治疗已进入了新药时代，硼替佐米及来那度胺等新药的应用使MM患者的疗效和预后得到显著改善 [<xref ref-type="bibr" rid="hanspub.42928-ref10">10</xref>]。本例患者预后分期为DS I期A，ISS I期，R-ISS I期，按照细胞遗传学风险分层和mSMART危险分层均为低危，然而在使用包含硼替佐米、来那度胺等新药治疗过程中的最佳疗效为SD，并且短期内死亡，说明本病例患者不适合依据传统风险分层系统评估其疗效及预后。此外，本例患者在极短时间内病情迅速恶化，与后期转化为浆母细胞骨髓瘤可能存在极大的关系。</p><p>PPCM又被称为浆母细胞型浆细胞瘤，最早由Bart [<xref ref-type="bibr" rid="hanspub.42928-ref11">11</xref>] 在1982年提出，将骨髓瘤细胞分为浆母细胞型和浆细胞型。Greipp等1985年按照细胞形态又将骨髓瘤细胞分类为成熟型骨髓瘤细胞、中间型骨髓瘤细胞、未成熟型骨髓瘤细胞和浆母细胞型骨髓瘤细胞，当骨髓中浆母细胞占骨髓有核细胞 &gt; 2%时，可诊断为浆母细胞骨髓瘤 [<xref ref-type="bibr" rid="hanspub.42928-ref3">3</xref>]。SAILER等 [<xref ref-type="bibr" rid="hanspub.42928-ref12">12</xref>] 总结了153例病例，认为浆母细胞 &gt; 30%时可考虑为PPCM。后来，国内外研究者较常沿用病理描述的浆母细胞。PPCM的浆母细胞形态学特征为：染色质疏松、胞核直径 &gt; 10 μm或核仁 &gt; 2 μm、胞质较少、核质比较高；浆母细胞是一种较多出现在晚期髓外复发中的细胞形态，PPCM主要依靠病理学及免疫组织化学检查确诊 [<xref ref-type="bibr" rid="hanspub.42928-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.42928-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.42928-ref15">15</xref>]。相比较于非PPCM，PPCM倾向于表现为更严重、更具侵略性的特征，多表现为贫血，肾功能不全，高钙血症，浆细胞百分比较高，浆细胞标记指数(PCLI)和β2-微球蛋白较高，白蛋白水平较低以及髓外浸润 [<xref ref-type="bibr" rid="hanspub.42928-ref15">15</xref>]。对于非分泌型的PPCM，建议在进行治疗之前先进行F-FDG-PET检查 [<xref ref-type="bibr" rid="hanspub.42928-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.42928-ref17">17</xref>]。</p><p>2000年以来，国内外文献报道PPCM的个案报道较少，文献对PPCM多为临床特征、免疫表型的描述性研究；对PPCM的治疗以及预后的相关研究和文献报道较少。自2000年以来国内外关于PPCM个案报道19例；回顾分析了包含本中心1例在内的浆母细胞骨髓瘤共计20例，女性患者7例，男性患者13例，年龄分布在35~83岁。80% (16/20)患者年龄 &lt; 65岁。11例为原发性浆母细胞骨髓瘤，8例为继发性浆母细胞骨髓瘤，1例诊断介于PPCM与浆母细胞淋巴瘤之间无法明确，但是抗骨髓瘤治疗治疗有效。55% (11/20)患者伴有贫血，50% (10/20)患者伴有髓外浸润。75% (15/20)患者伴有骨破坏。IgG占35.3% (6/17)，IgA占17.6% (3/17)，IgD占11.8% (2/17)，IgM占5.9% (1/17)，IgE占5.9% (1/17)，非分泌占5.9% (1/17)，κ轻链型占11.8% (2/17)，λ轻链型占5.9% (1/17)。10例患者骨髓涂片浆细胞阳性，异常浆细胞比例的中位数为52.5% (20.67%~100%)。9例患者ki-67为阳性，均≥90%。免疫组化结果显示CD38阳性占100% (9/9)，CD138阳性93.8% (15/16)，CD56阳性66.7% (6/9)，CD20阴性86.7% (13/15)。13例有治疗记录的患者中，12例患者接受包含蛋白酶体抑制剂或免疫调节剂在内的联合手术或放化疗，1例患者接受传统药物治疗；4例患者进行移植治疗，其中1例接受包含硼替佐米、达雷木单抗在内的化疗联合放疗及自体干细胞移植(获得较好的生存)，1例接受包含卡非佐米在内的化疗加自体干细胞移植(获得完全缓解，总生存期为67个月)。</p><p>PPCM是具有侵袭性的浆细胞肿瘤亚型，其发病机制仍未阐明，目前有以下三个观点：1) Yaccoby提出破骨细胞的脱分化 [<xref ref-type="bibr" rid="hanspub.42928-ref18">18</xref>]；2) 潜在机制可能与ras突变和血清可溶性IL-6R增高有关 [<xref ref-type="bibr" rid="hanspub.42928-ref15">15</xref>]；3) 可能与MM存在区域内异质性有关 [<xref ref-type="bibr" rid="hanspub.42928-ref19">19</xref>]。</p><p>临床上常见的与PPCM相似疾病有浆母细胞淋巴瘤(plasmablastic lymphoma, PBL)、间变性浆细胞骨髓瘤(anaplastic plasma cell myeloma, APCM)。正常浆细胞免疫表型为CD38+ CD138+ CD19+ CD56− CD117− CD20−，而在许多MM浆细胞中CD19表达消失或明显降低，CD20、CD56和CD117表达升高 [<xref ref-type="bibr" rid="hanspub.42928-ref20">20</xref>]，而PBL免疫表型特征几乎与PPCM相同。PPCM形态上与PBL相似，但通常为EBV阴性。PBL是一种侵袭性大B细胞淋巴瘤，多发生于口腔外和淋巴结，HIV病毒和EB病毒感染可为阴性。形态学上，PBL表现为浆母细胞与成熟浆细胞的混合；虽然PBL是一种B细胞淋巴瘤，表达浆细胞的细胞表型CD138，CD38和MUM1+，但不表达B细胞的标志物CD20和PAX-5 [<xref ref-type="bibr" rid="hanspub.42928-ref21">21</xref>]，EBV多数为阳性。APCM是一种罕见的的难治性骨髓瘤，年轻患者常见，且多为IgA型，易侵犯髓外组织，通常伴有1q21扩增或17p (p53)缺失，t (4; 14)和/或13号染色体异常，预后非常差。APCM细胞形态表现为多形性，可在疾病初期或进展期出现 [<xref ref-type="bibr" rid="hanspub.42928-ref22">22</xref>]。</p><p>浆细胞肿瘤一般应用包含糖皮质激素、蛋白酶体抑制剂、免疫调节剂和烷化剂等在内的方案常规剂量或者高剂量治疗以及自体干细胞移植。具有浆母细胞形态的浆细胞是存活不良的独立预测因子 [<xref ref-type="bibr" rid="hanspub.42928-ref23">23</xref>]，尽管干细胞移植可以提高PPCM的缓解率和总体生存率，但PPCM仍是MM中预后最差的类型 [<xref ref-type="bibr" rid="hanspub.42928-ref24">24</xref>] [<xref ref-type="bibr" rid="hanspub.42928-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.42928-ref26">26</xref>]。最近研究表明，硼替佐米和来那度胺联合依托泊苷、泼尼松、长春新碱、环磷酰胺和阿霉素(EPOCH)治疗PBL是可行和有效的 [<xref ref-type="bibr" rid="hanspub.42928-ref27">27</xref>]。因此，我们推断EPOCH方案具有治疗PPCM的潜力。本例患者，确诊为IgD型PPCM后，建议使用新药联合传统药物化疗，行自体或者异体移植，条件允许情况下行CAR-T细胞免疫疗法，由于患者依从性差，拒绝治疗。</p><p>高度重视组织病理及细胞形态学检查对于骨髓瘤诊断、预后判断和指导治疗极其重要，尤其是浆母细胞型、间变型等罕见的高度侵袭性骨髓瘤类型。本病例患者分期早，危险分层为低危，尽管应用包含硼替佐米及来那度胺在内的新药方案治疗，仍然短期内死亡，表明合并IgD和浆母细胞这两种类型骨髓瘤特征的患者预后极差。传统的临床分期系统未涉及关于IgD亚型的描述，因此我们仍然需要加大研究IgD型、浆母细胞型等罕见骨髓瘤亚型的样本量，寻找更多的循证医学证据支持。骨髓瘤在疾病进展中出现浆母细胞，可作为疾病发生恶性变化的重要提示性因素，往往治疗效果欠佳，一旦确诊PPCM后，我们必须早期积极治疗，早期使用包含新药在内的联合抗骨髓瘤治疗，必要时联合使用细胞毒药物及手术治疗，尤其对于年轻患者早期使用自体或者异基因造血干细胞移植，条件允许情况下行CAR-T细胞免疫疗法，使其生存期延长。</p></sec><sec id="s8"><title>文章引用</title><p>肖晶晶,聂淑敏,黄俊霞,李田兰,周静静,冯献启. IgD型浆母细胞骨髓瘤一例报告并文献复习IgD Plasmablastic Plasma Cell Myeloma: A Case Report and Literature Review[J]. 临床医学进展, 2021, 11(06): 2514-2520. https://doi.org/10.12677/ACM.2021.116361</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.42928-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">罗子怡, 周芙玲. 2019年美国国立综合癌症网多发性骨髓瘤诊治的指南更新解读[J]. 临床内科杂志, 2020, 37(1): 71-72.</mixed-citation></ref><ref id="hanspub.42928-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Banerjee, S.S., Verma, S. and Shanks, J.H. (2004) Morphological Variants of Plasma Cell Tumours. Histopathology, 44, 2-8. &lt;br&gt;https://doi.org/10.1111/j.1365-2559.2004.01763.x</mixed-citation></ref><ref id="hanspub.42928-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Greipp, P.R., Raymond, N.M., Kyle, R.A., et al. (1985) Multiple Myeloma: Significance of Plasmablastic Subtype in Morphological Classification. Blood, 65, 305-310. &lt;br&gt;https://doi.org/10.1182/blood.V65.2.305.305</mixed-citation></ref><ref id="hanspub.42928-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Shivlal, P. and Kyle, R.A. (2013) Unusual Myelomas: A Review of IgD and IgE Variants. Oncology (Williston Park, N. Y.), 27, 798-803.</mixed-citation></ref><ref id="hanspub.42928-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">张磊, 刘会兰, 郑昌成, 朱小玉, 汤宝林, 耿良权, 吴竞生, 朱薇波, 刘欣, 郑辉, 孙自敏. 17例IgD型多发性骨髓瘤临床分析[J]. 临床血液学杂志, 2015, 28(1): 12-15+18.</mixed-citation></ref><ref id="hanspub.42928-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">安然, 何海燕, 姜华, 李璐, 赵云阳, 吴昊, 贺婕, 张慧, 侯健. 130例IgD型多发性骨髓瘤临床特点及预后分析[J]. 临床血液学杂志, 2017, 30(3): 194-197.</mixed-citation></ref><ref id="hanspub.42928-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Liu, J., Hu, X., Jia, Y., et al. (2020) Clinical Features and Survival Outcomes in IgD Myeloma: A Study by Asia Myeloma Network (AMN). Leukemia. &lt;br&gt;https://doi.org/10.1038/s41375-020-01060-w</mixed-citation></ref><ref id="hanspub.42928-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Shimamoto, Y., Anami, Y. and Yamaguchi, M. (1991) A New Risk Grouping for IgD Myeloma Based on Analysis of 165 Japanese Patients. European Journal of Haematology, 47, 262-267.  
&lt;br&gt;https://doi.org/10.1111/j.1600-0609.1991.tb01569.x</mixed-citation></ref><ref id="hanspub.42928-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Liao Arter, Z.H., Miles, D., Mignano, S., et al. (2020) Plasmablastic IgM Multiple Myeloma with Hypocellular Bone Marrow. Annals of Hematology, 99, 895-896. &lt;br&gt;https://doi.org/10.1007/s00277-020-03959-x</mixed-citation></ref><ref id="hanspub.42928-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Zagouri, F., Kastritis, E., Symeonidis, A.S., Giannakoulas, N., et al. (2014) Dimopoulos. Immunoglobulin D Myeloma: Clinical Features and Outcome in the Era of Novel Agents. European Journal of Haematology, 92, 308-312.  
&lt;br&gt;https://doi.org/10.1111/ejh.12255</mixed-citation></ref><ref id="hanspub.42928-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Bartl, R., Frisch, B., Burkhardt R., Fateh-Moghadam, A., et al. (1982) Bone Marrow Histology in Myeloma: Its Importance in Diagnosis, Prognosis, Classification and Staging. British Journal of Haematology, 51, 361-375.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2141.1982.tb02791.x</mixed-citation></ref><ref id="hanspub.42928-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sailer, M., Vykoupil, K.F., Peest, D., et al. (1995) Prognostic Relevance of a Histologic Classification System Applied in Bone Marrow Biopsies from Patients with Multiple Myeloma: A Histopathological Evaluation of Biopsies from 153 Untreated Patients. European Journal of Haematology, 54, 137-146.  
&lt;br&gt;https://doi.org/10.1111/j.1600-0609.1995.tb00204.x</mixed-citation></ref><ref id="hanspub.42928-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Giampaolo, T., Federica, C., Maurizio, Z., et al. (2006) Clinical and Biological Features of Multiple Myeloma Involving the Gastrointestinal System. Haematologica, 91, 964-967.</mixed-citation></ref><ref id="hanspub.42928-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Joan, B., de Larrea Carlos, F., Laura, R., et al. (2011) Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29, 3805-3812. &lt;br&gt;https://doi.org/10.1200/JCO.2011.34.9290</mixed-citation></ref><ref id="hanspub.42928-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Greipp, P.R., Leong, T., Bennett, J.M., et al. (1998) Plasmablastic Morphology—An Independent Prognostic Factor with Clinical and Laboratory Correlates: Eastern Cooperative Oncology Group (ECOG) Myeloma Trial E9486 Report by the ECOG Myeloma Laboratory Group. Blood, 91, 2501-2507. &lt;br&gt;https://doi.org/10.1182/blood.V91.7.2501</mixed-citation></ref><ref id="hanspub.42928-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Kaibara, H., Kaida, H., Ishibashi, M., et al. (2009) 18 F-FDG-PET Findings of Rare Case of Nonsecretory Plasmablastic Myeloma. Annals of Nuclear Medicine, 23, 807-811. &lt;br&gt;https://doi.org/10.1007/s12149-009-0300-2</mixed-citation></ref><ref id="hanspub.42928-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Møller, H.E.H., Preiss, B.S., Pedersen, P., et al. (2015) Clinicopathological Features of Plasmablastic Multiple Myeloma: A Population-Based Cohort. APMIS, 123, 652-658. &lt;br&gt;https://doi.org/10.1111/apm.12411</mixed-citation></ref><ref id="hanspub.42928-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Shmuel, Y. (2005) The Phenotypic Plasticity of Myeloma Plasma Cells as Expressed by Dedifferentiation into an Immature, Resilient, and Apoptosis-Resistant Phenotype. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11, 7599-7606. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-05-0523</mixed-citation></ref><ref id="hanspub.42928-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Fakhri, B. and Vij, R. (2016) Clonal Evolution in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 16, S130-S134. &lt;br&gt;https://doi.org/10.1016/j.clml.2016.02.025</mixed-citation></ref><ref id="hanspub.42928-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">邱荃, 朱平, 王茫桔, 等. 初诊多发性骨髓瘤患者CD56和CD19表达与染色本核型及预后的关系[J]. 中国实验血液学杂志, 2016, 24(4): 1071-1078.</mixed-citation></ref><ref id="hanspub.42928-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Swerdlow, S.H., Campo, E., Harris, N.L., et al. (2008) WHO Classification of Tumors. In: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, 256-257.</mixed-citation></ref><ref id="hanspub.42928-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Shenon, S. and Ira, M. (2016) Plasma Cell Myeloma with Anaplastic Transformation. Blood, 128, 2106.  
&lt;br&gt;https://doi.org/10.1182/blood-2016-08-731844</mixed-citation></ref><ref id="hanspub.42928-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Ribourtout, B. and Zandecki, M. (2015) Plasma Cell Morphology in Multiple Myeloma and Related Disorders. Morphologie, 99, 38-62. &lt;br&gt;https://doi.org/10.1016/j.morpho.2015.02.001</mixed-citation></ref><ref id="hanspub.42928-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Rajkumar, S.V., Fonseca, R., Lacy, M.Q., et al. (1999) Plasmablastic Morphology Is an Independent Predictor of Poor Survival after Autologous Stem-Cell Transplantation for Multiple Myeloma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 17, 1551-1557. &lt;br&gt;https://doi.org/10.1200/JCO.1999.17.5.1551</mixed-citation></ref><ref id="hanspub.42928-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Licci, S. (2017) Duodenal Localization of Plasmablastic Myeloma. World Journal of Gastrointestinal Pathophysiology, 8, 93-95. &lt;br&gt;https://doi.org/10.4291/wjgp.v8.i2.93</mixed-citation></ref><ref id="hanspub.42928-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Reddy, R., Vohra, S. and Macurak, R. (2015) Secondary Extramedullary Plasmablastic Myeloma of the Small Bowel. Clinical Gastroenterology and Hepatology, 13, A23-A24. &lt;br&gt;https://doi.org/10.1016/j.cgh.2015.06.029</mixed-citation></ref><ref id="hanspub.42928-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Castillo, J.J., Guerrero-Garcia, T., Baldini, F., et al. (2019) Bortezomib plus EPOCH Is Effective as Frontline Treatment in Patients with Plasmablastic Lymphoma. British Journal of Haematology, 184, 679-682.  
&lt;br&gt;https://doi.org/10.1111/bjh.15156</mixed-citation></ref></ref-list></back></article>